Beech Wood Xylan Deacetylation for Pentosan Polysulfate Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current manufacturing processes for pentosan polysulfate, such as those used in pharmaceutical products like Elmiron®, do not fully control and characterize structural elements like branching, sulfate group position, and acetylation degree, affecting clinical efficacy and safety, and lack complete structural characterization.
Innovation Solution
A process involving selective deacetylation and isomerization of xylan from beech wood, using basic reagents like sodium hydroxide and pyridine, to produce a polysaccharide with specific structural elements matching those found in pharmaceutical pentosan polysulfate, ensuring precise pharmacological profiles and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional sulfation processes are used to produce pentosan polysulfate, then the product can be manufactured, but the structural elements (branching, sulfate group position, acetylation degree) cannot be fully controlled and characterized
Solution Approach 1:
The patent segments the conventional single-step sulfation process into multiple controlled stages: (1) selective deacetylation of xylan to remove excess acetyl groups while preserving structural elements, (2) isomerization to create specific reducing end units, and (3) controlled sulfation. This segmentation allows precise control over each structural parameter independently, resolving the contradiction between manufacturing precision and process complexity by making the complex process manageable through systematic breakdown.
Solution Approach 2:
The patent applies preliminary actions before the main sulfation reaction: selective deacetylation is performed first to establish the correct acetylation profile, followed by isomerization to create specific reducing end units (xylose, lyxose, or xylulose). These preliminary steps prepare the substrate with predetermined structural characteristics, ensuring that the subsequent sulfation produces the desired structural elements with precise control over sulfate group positions and branching patterns.
2Reliability
If structural elements are not fully controlled, then manufacturing is simpler, but clinical efficacy and safety are affected
Solution Approach 1:
The patent systematically changes key parameters to achieve reliable clinical efficacy: (1) controls the degree of deacetylation to maintain specific acetylation patterns, (2) regulates isomerization conditions to produce specific reducing end units, and (3) optimizes sulfation parameters to achieve desired sulfate group positioning. By precisely controlling these parameters, the process ensures consistent structural elements that guarantee clinical efficacy and safety while maintaining manufacturing feasibility through well-defined process conditions.
3Manufacturing precision
If complete structural characterization is implemented, then pharmacological profile is ensured, but manufacturing process becomes more complex
Solution Approach 1:
The patent implements feedback control through comprehensive structural characterization at each stage: NMR spectroscopy monitors deacetylation程度 and isomerization products, while analytical methods track sulfate group positioning and molecular weight distribution. This feedback enables real-time adjustment of process parameters to maintain desired structural elements, ensuring pharmacological profile consistency. The feedback system balances manufacturing precision with productivity by enabling quality control without requiring excessive process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures the production of pentosan polysulfate with consistent structural elements, improving therapeutic efficacy and safety by maintaining the desired molecular weight, sulfation degree, and acetylation profile, aligning with regulatory requirements for generic drug authorization.
Implementation Method 1
selective deacetylation of xylan extracted from beech wood... step a) or step d) is performed in the presence of a basic reagent, preferably aqueous sodium hydroxide
Implementation Method 2
step b) or step c) is performed by heating deacetylated xylan achieved in step a) or xylan extracted from beech wood in presence of pyridine; and in step b) or in step c) some of the xylose units at the reducing end of the polysaccharide chains are isomerized into lyxose or xylulose units
Data Source
Figure 1
AI summary
The present invention relates to a process for the preparation of a polysaccharide composed of D-xylose units of formula (III) linked together via beta 1,4 glycosidic bonds wherein R1 is hydrogen or acetyl, R2 is hydrogen, acetyl or a 4-O-methyl glucuronic acid unit, wherein, when R2 is a 4-O-methyl glucuronic acid unit, the R1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.